论文部分内容阅读
1977年Speris 首次报告从病人和患病动物中分离的某些大肠艾希氏菌(E Coli)菌株能产生Vero 细胞毒素(VT)。接着,Konowalchuk指出VT 可能是人类腹泻病的另一重要致病因子,并把这些菌株称作产Vero 毒素大肠艾希氏菌(VTEC)。然而,VTEC 与人类疾病的关系直到近年才确立。1982年,E Coli O_(157):H_7血清型在美国引起一次累及几个州的出血性结肠炎(HC)暴发不但HC 的病源学诊断逐渐得以明确,而且VTEC 引起溶血性尿毒综合症(HUS)和血小板减少性紫癜(TTP)的证据也不断增多。在一些欧、美国家中,VTEC 作为一种肠道致病菌已经成为一个重要的公共卫生问题,引起了许多学者的关注。现将有关VTEC 的临床和流行病学研究进展作一综述。
In 1977, Speris first reported that some strains of Escherichia coli (E Coli) isolated from patients and diseased animals produce Vero cytotoxin (VT). Next, Konowalchuk pointed out that VT may be another important causative agent of human diarrheal disease and refers to these strains as Vero toxin-producing Escherichia coli (VTEC). However, the relationship between VTEC and human diseases was established only recently. In 1982, E Coli O_ (157): H_7 serotype caused an outbreak of hemorrhagic colitis (HC) in several states in the United States. Not only the etiological diagnosis of HC gradually became clear, but VTEC caused hemolytic uremic syndrome (HUS ) And thrombocytopenic purpura (TTP) evidence is also increasing. In some European and American countries, VTEC as an intestinal bacteria has become an important public health issue, aroused the concern of many scholars. The progress of clinical and epidemiological studies on VTEC is reviewed.